Related references
Note: Only part of the references are listed.Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma
Sagar Lonial et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Multiple myeloma: Role of autologous transplantation
Ioannis Ntanasis-Stathopoulos et al.
CANCER TREATMENT REVIEWS (2020)
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention
Zunyou Wu et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Sagar Lonial et al.
LANCET ONCOLOGY (2020)
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
Wenhua Liang et al.
LANCET ONCOLOGY (2020)
Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools
Despina Fotiou et al.
CANCERS (2020)
Multiple myeloma: 2020 update on diagnosis, risk-stratification and management
S. Vincent Rajkumar
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Hematological findings and complications of COVID-19
Evangelos Terpos et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Testing for COVID-19 in lung cancer patients
A. Passaro et al.
ANNALS OF ONCOLOGY (2020)
Managing COVID-19 in the oncology clinic and avoiding the distraction effect
F. Cortiula et al.
ANNALS OF ONCOLOGY (2020)
Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China
L. Zhang et al.
ANNALS OF ONCOLOGY (2020)
Care of haematology patients in a COVID-19 epidemic
John Willan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China
Ruchong Chen et al.
CHEST (2020)
Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age
Monika Engelhardt et al.
HAEMATOLOGICA (2020)
Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy
Giacomo Grasselli et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Demographic science aids in understanding the spread and fatality rates of COVID-19
Jennifer Beam Dowd et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak
Mengyuan Dai et al.
CANCER DISCOVERY (2020)
Considerations for Drug Interactions on QTc Interval in Exploratory COVID-19 Treatment
Dan M. Roden et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal
Masumi Ueda et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Recommendations from national regulatory agencies for ongoing cancer trials during the COVID-19 pandemic
Bruno H. R. de Paula et al.
LANCET ONCOLOGY (2020)
Frequently asked questions regarding SARS-CoV-2 in cancer patients-recommendations for clinicians caring for patients with malignant diseases
Marie Von Lilienfeld-Toal et al.
LEUKEMIA (2020)
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
Maria-Victoria Mateos et al.
LANCET HAEMATOLOGY (2020)
Clinical Characteristics of Covid-19 in New York City
Parag Goyal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions
Laure Elens et al.
THERAPEUTIC DRUG MONITORING (2020)
Caring for older adults with multiple myeloma during the COVID-19 Pandemic: Perspective from the International Forum for Optimizing Care of Older Adults with Myeloma
Hira Mian et al.
JOURNAL OF GERIATRIC ONCOLOGY (2020)
First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab
Xuhan Zhang et al.
BLOOD ADVANCES (2020)
COVID-19 and Cancer: Lessons From a Pooled Meta-Analysis
Aakash Desai et al.
JCO GLOBAL ONCOLOGY (2020)
Myeloma bone disease: from biology findings to treatment approaches
Evangelos Terpos et al.
BLOOD (2019)
Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study
Habte Yimer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma
Hareth Nahi et al.
PLOS ONE (2019)
The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG)
Charalampia Kyriakou et al.
BLOOD CANCER JOURNAL (2019)
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau et al.
LANCET (2019)
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma
Laura Rosinol et al.
BLOOD (2019)
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma
Ajai Chari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations
Corrado Girmenia et al.
BLOOD REVIEWS (2019)
Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study
Rasmus Sorrig et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Michel Attal et al.
LANCET (2019)
Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial
Mark T. Drayson et al.
LANCET ONCOLOGY (2019)
Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies
Min Chen et al.
ANNALS OF HEMATOLOGY (2018)
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis
Sara Bringhen et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2018)
Ninety-minute daratumumab infusion is safe in multiple myeloma
Hallie Barr et al.
LEUKEMIA (2018)
Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria
Arjun Lakshman et al.
BLOOD CANCER JOURNAL (2018)
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)
Sara Bringhen et al.
HAEMATOLOGICA (2018)
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
Meletios A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma
Xiaoyan Feng et al.
CLINICAL CANCER RESEARCH (2017)
Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study
Noopur Raje et al.
CLINICAL CANCER RESEARCH (2016)
Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma Database
Morten O. Holmstrom et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications
Evangelos Terpos et al.
HAEMATOLOGICA (2015)
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications
Evangelos Terpos et al.
HAEMATOLOGICA (2015)
Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients
Cecilie Blimark et al.
HAEMATOLOGICA (2015)
Changing treatment paradigms for patients with plasma cell myeloma: Impact upon immune determinants of infection
Benjamin W. Teh et al.
BLOOD REVIEWS (2014)
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2014)
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma
M. A. Dimopoulos et al.
LEUKEMIA (2014)
International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma-Related Bone Disease
Evangelos Terpos et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
Maria-Victoria Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide
Alessandra Larocca et al.
BLOOD (2012)
The Proteasome Inhibitor Bortezomib Enhances the Susceptibility to Viral Infection
Michael Basler et al.
JOURNAL OF IMMUNOLOGY (2009)
Share Paper
